Glioblastoma patients may benefit from a vaccine-chemotherapy combination

(American Association for Cancer Research) A vaccine targeting cytomegalovirus (CMV) antigen pp65, combined with high-dose chemotherapy (temozolomide), improved both progression-free survival and overall survival for a small group of glioblastoma (GBM) patients.